Sat, Sep 20, 2014, 7:09 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

La Jolla Pharmaceutical Co. Message Board

  • LA JOLLA PHARMACEUTICAL�S NEW DRUG APPLICATION FOR
    LUPUS DRUG CANDIDATE RIQUENT� ACCEPTED FOR REVIEW BY
    FDA
    SAN DIEGO, February 17, 2004 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC)
    today announced that the Company�s New Drug Application (NDA) for Riquent� has
    been accepted for review by the United States Food and Drug Administration (FDA).
    Riquent is designed to treat lupus patients with renal disease, a primary cause of
    sickness and death among these patients. Riquent is the first drug candidate
    specifically developed for the treatment of lupus renal disease in more than 30 years.
    �The acceptance of our NDA filing is an important step for the Company. This milestone
    brings us closer to achieving our goal of providing long-suffering lupus patients with a
    new therapy,� said Steve Engle, Chairman and CEO of La Jolla Pharmaceutical
    Company.
    About Lupus
    Lupus (systemic lupus erythematosus or SLE) is a chronic, life-threatening autoimmune
    disease. About 90% of lupus patients are female, and many develop the disease during
    their childbearing years. Approximately 50% of lupus patients have renal disease,
    which can lead to irreversible kidney damage, kidney failure and the need for dialysis.
    Latinos, African Americans, and Asians face an increased risk of serious renal disease
    associated with lupus.
    The current standard of care for lupus renal disease often involves treatment with high
    doses of corticosteroids and immunosuppressive drugs that can cause severe side
    effects including diabetes, hypertension and sterility, and may leave patients vulnerable
    to opportunistic infections.

    Happy investing,

    andras

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
LJPC
8.95-0.20(-2.19%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.